Group 1 - The recent surge in A-share companies planning to list in Hong Kong, with 25 companies announcing plans since September and 76 others awaiting hearings as of October 2 [1][3] - Active participation from pharmaceutical companies such as Kexing Pharmaceutical, Newway, and Borui Pharmaceutical, alongside firms from various sectors like automotive and consumer goods [3] - The "A+H" dual listing model has become increasingly significant, with 11 A-share companies completing "A+H" listings this year, raising a total of 916.89 billion HKD [3] Group 2 - Notable fundraising amounts from five companies: Ningde Times (410.06 billion HKD), Heng Rui Pharmaceutical (113.74 billion HKD), Sanhua Intelligent Control (107.36 billion HKD), Haitian Flavoring and Food (105.71 billion HKD), and Lens Technology (54.83 billion HKD), collectively accounting for over 50% of this year's total IPO financing in Hong Kong [3] - The total financing amount for Hong Kong stocks reached 1,345 billion HKD by the end of August, marking a nearly sixfold increase compared to the same period in 2024 [3] - The "A+H" model accounted for 70% of the total fundraising in the first half of the year, highlighting the dynamic interconnection between the Shanghai, Shenzhen, and Hong Kong markets [3]
9月25家A股公司筹划赴港上市 医药企业成主力
Huan Qiu Wang·2025-10-06 03:45